Zenas BioPharma, Inc.

ZBIO

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Rock Springs Capital EcoR1 Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 502,077Value: $18.2M

# Signal Note: Rock Springs Capital initiates $18.2M position in ZBIO Rock Springs' entry into ZBIO likely signals conviction in the company's late-stage pipeline; key near-term catalysts include Phase 2b data for ZB201 in systemic sclerosis (expected 2024-2025) and potential regulatory progression for ZB375 in atopic dermatitis. The healthcare specialist's initiation of a concentrated position across a smaller market-cap biotech suggests asymmetric risk/reward positioning ahead of these clinical milestones. Monitor upcoming data readouts and any partnering announcements as validation of the thesis.

EcoR1 CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NUVB2 funds NGNE2 funds BBIO2 funds IMNM2 funds MBX2 funds CNTA2 funds JAZZ2 funds PCVX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: EcoR1 Capital Initiates $28.7M Position in Zenas BioPharma EcoR1's entry into ZBIO signals conviction in the company's pipeline, likely driven by ZEN-797 (selective PI3K delta inhibitor) for autoimmune/inflammatory indications where EcoR1 has demonstrated thesis conviction. The $28.7M position size and growth-stage/crossover focus suggest near-term inflection catalysts, potentially including clinical data readouts or regulatory meetings within the next 12-18 months that could de-risk commercialization timelines.